Jump to content

Domantis' Dual Targeting Domain Antibodies Shown to Kill


dadstimeon

Recommended Posts

Multiple Myeloma Cells and Spare Healthy Cells

http://www.pharmalive.com/News/index.cf ... egoryid=15

- Revolutionary Approach to Cancer Therapy Should Increase Efficacy, Reduce Toxicity for Many Oncology Indications -

WALTHAM, Mass. and CAMBRIDGE, England, December 06, 2005 /PRNewswire/ -- Domantis, the human Domain Antibody (dAb) therapeutics company, today presented data showing how dual targeting dAbs (a pair of linked dAbs in a single product, each of which binds to a different target) have been used to specifically target multiple myeloma cells, while sparing healthy cells.

Speaking at IBC's 16th International Conference on Antibody Engineering in San Diego, U.S., Domantis' Executive Vice President and CSO, Dr. Ian Tomlinson explained, "Domantis scientists have shown in a series of experiments that dual targeting dAbs which bind to two different antigens on the surface of tumor cells can preferentially bind to and kill those tumor cells while healthy cells that express only one or neither of the antigens are spared. This is a completely novel approach to tumor targeting that dramatically enhances the potency of the targeting agent by focusing its activity on tumor cells. This cannot be achieved using conventional antibodies which bind to a single target and typically kill both cancerous and non-cancerous cells."

Since it first announced the successful creation of dual targeting dAbs in 2003, Domantis has initiated three proprietary dual targeting oncology programs, initially focused on multiple myeloma, small cell lung cancer and colorectal cancer. The first two of these programs harness the ability of dual targeting dAbs to specifically target tumor cells. Most oncology drugs on the market or in development kill a broad spectrum of cells, including both cancerous and non-cancerous cells. Even blockbuster antibody therapeutics such as Rituxan are aimed at killing all B cells, rather than just those that are malignant. By enhancing the targeting of tumor cells while sparing healthy cells Domantis hopes to develop the next generation of cancer drugs, based on the unique attributes of dAbs, that are more effective and less toxic than those currently on the market.

In addition to creating better cancer drugs, dual targeting dAbs have significant potential in the treatment of multi-factorial diseases, where a number of different disease targets are implicated. Domantis has already shown that dual targeting dAbs can bind and neutralize two completely different therapeutic targets in formats that can easily be produced in microbial or mammalian cells. The Company has created a panel of proprietary dual targeting dAbs against several different pairs of targets, including one to treat asthma that neutralizes the activities of both IL-4 and IL-13. As part of its ongoing collaboration with Abbott Laboratories, Domantis has also delivered to Abbott a dual targeting dAb directed at two inflammatory disease targets. Domantis has filed a series of patent applications covering the methods of production and compositions of dual targeting dAbs.

Notes to Editors

Domantis is a drug development company that is leveraging its proprietary dominance in human dAbs to deliver therapies which address large, unmet medical needs including inflammation, cancer, respiratory and autoimmune diseases. In less than three years it has initiated more than a dozen proprietary therapeutic programs including preclinical dAb therapeutics for the treatment of rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), asthma, and colorectal cancer.

Therapeutic antibodies are a major commercial opportunity. Seventeen monoclonal antibodies have been approved for use to date and these are expected to generate sales exceeding $9 billion by 2006. Fully human dAbs, the smallest possible binding fragments of full antibodies, combine the therapeutic benefits of small molecule drugs (formulation and administration versatility, wide therapeutic target range, low cost) with those of full human antibodies (enormous diversity, high specificity, lower toxicity). Thus they have very broad therapeutic relevance.

The growing antibody market and the commercial potential of dAbs makes Domantis an attractive partner for the pharmaceutical industry and it has already struck deals with Bristol-Myers Squibb, Peptech, Abbott Laboratories, ImClone, Tanox and Argenta Discovery whilst also attracting funding from the European Union for several therapeutic collaborations. A series of dAb therapies derived from these collaborations should begin to enter the clinic in 2007.

Monoclonal antibodies were invented in the 1970's at the UK Medical Research Council's Laboratory of Molecular Biology (MRC-LMB), which has remained at the forefront of therapeutic antibody research since that time. In 1989, scientists in the LMB laboratories of Sir Gregory Winter published the discovery of dAbs. This discovery led to the creation of an extensive portfolio of intellectual property covering the development and use of dAbs, the binding domains of fully human antibodies. Domantis has exclusive licenses and assignments to these pioneering inventions for dAb products and extensive intellectual property covering dAb libraries, methods of discovery, compositions, and formulations of dAbs. As a result, Domantis is the only company capable of fully exploiting the commercial therapeutic applications of human dAbs.

Sir Gregory and Dr Ian Tomlinson, world-renowned scientists from the MRC- LMB, launched Domantis in December 2000. Sir Gregory was also a founder of Cambridge Antibody Technology (CAT) plc. To date Domantis has raised $54 million from investors including 3i, Gray Ghost, Albany Ventures, MVM Limited, ISIS and Peptech Limited. Domantis employs over 50 staff and has laboratory facilities in Cambridge, UK and commercial offices in Waltham, Massachusetts, U.S. See also http://www.domantis.com.

CONTACT: Robert Connelly, CEO of Domantis, +1-781-250-2833; or Europe:Nicki Brimicombe of NB PR, +44-1883-732353; or USA: Ted Agne of ComStratGroup, +1-781-631-3117

Web site: http://www.domantis.com//

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.